NCT05433532View on ClinicalTrials.gov

Study of Azacitidine，Venetoclax，and Flumatinib in Newly Diagnosed Ph-positive Acute Leukemia and CML-AP/BP Patients

PHASE2CompletedINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

May 1, 2022

Primary Completion Date

April 13, 2024

Study Completion Date

April 13, 2024

Conditions
Philadelphia ChromosomeAcute Myeloid LeukemiaAcute Lymphoblastic LeukemiaChronic Myeloid LeukemiaMixed Phenotype Acute Leukemia
Interventions
DRUG

Azacitidine

Azacitidine: 75mg/m2 qd, d1-d7, subcutaneous injection

DRUG

Venetoclax

Venetoclax: 100mg d1, 200mg d2, 300mg d3, 400mg d4-d14 or 21, oral (Adjusted according to the peripheral blood BCR/ABL1 results on day 14)

DRUG

Flumatinib

Flumatinib: 600mg qd, d4-d21, oral

Trial Locations (1)

215006

The First Affiliated Hospital of Soochow University, Suzhou

All Listed Sponsors
lead

The First Affiliated Hospital of Soochow University

OTHER